The cerebellum: a transdiagnostic personalised target for neuromodulation in psychiatry

Description du projet

Exploiter le cervelet pour traiter les symptômes psychiatriques résistants

Outre la coordination des mouvements, le cervelet joue également un rôle dans la façon dont nous pensons et ressentons les choses. Bien qu’il n’occupe que 10 % du volume du cerveau, il abrite plus de la moitié de nos neurones. Nombre d’entre eux sont connectés aux zones responsables de la pensée supérieure, ce qui fait du cervelet une cible de choix pour la stimulation cérébrale non invasive. Le projet CLOVIS, financé par le CER, entend exploiter ce lien pour traiter des symptômes de la schizophrénie ou du trouble bipolaire, notamment ceux qui ne répondent pas bien aux traitements standard. Il recourra à des modèles d’IRM et à des enregistrements directs du cerveau. Les chercheurs détermineront exactement où et comment appliquer la stimulation pour obtenir les meilleurs résultats. L’objectif est de passer des théories de laboratoire à un essai clinique, en prouvant que la stimulation cérébrale personnalisée peut réellement améliorer le quotidien des personnes atteintes de ces maladies.

Objectif

Have you ever had that moment where you reach for something, convinced it is heavy, but it is actually light? Your arm jolts upward, correcting itself before you realise the difference. This split second adjustment is thanks to your cerebellum, the part of your brain responsible for fine-tuning movements by integrating sensory feedback. While the cerebellum is traditionally associated with motor control, it plays a similar role in cognitive functions. Despite occupying 10% of the brain’s volume, the cerebellum houses more than 50% of its neurons, many of which are integral to higher cognitive processes. Its extensive connections with brain regions responsible for complex thought and emotion make it a promising target for non-invasive brain stimulation (NIBS) especially in addressing the resistant cognitive and negative symptoms observed in psychiatric disorders such as schizophrenia, bipolar disorder, and autism. However, a significant challenge persists: clinical research on NIBS often relies on a trial-and-error approach, while fundamental research has yet to fully translate electrophysiological findings into circuit-level applications that can guide clinical interventions. To bridge this gap, I will develop normative models from large-scale MRI cohorts to identify patients who are most likely to benefit from cerebellar stimulation and then derive a personalised cerebellar target. Concurrently, animal studies using ultra-high field MRI will be conducted to determine optimal cerebellar stimulation parameters. With intracranial recordings, I will explore the neuroplastic changes induced by NIBS in humans. The project will culminate in a proof-of-concept clinical trial aiming at improving cognitive and negative symptoms across schizophrenia, bipolar disorder and autism with cerebellar NIBS. This multidisciplinary project has the potential to revolutionize the treatment of resistant psychiatric symptoms and catalyse advancements in the understanding of NIBS.